ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID.
- DOI
- 10.1136/bmjopen-2026-118726
- Published
- 2026 Jul 24
- Container
- BMJ open
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/bmjopen-2026-118726,
title = {ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID.},
author = {Markham P and Peluso MJ and Hsiang-Yi Chou S and McCorkell L and O'Quinn S and Reading C and Ahlem C and Petit CM and Yan J and Palumbo JM},
year = {2026},
journal = {BMJ open},
doi = {10.1136/bmjopen-2026-118726},
url = {https://doi.org/10.1136/bmjopen-2026-118726}
}RIS
TY - JOUR TI - ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID. AU - Markham P AU - Peluso MJ AU - Hsiang-Yi Chou S AU - McCorkell L AU - O'Quinn S AU - Reading C AU - Ahlem C AU - Petit CM AU - Yan J AU - Palumbo JM PY - 2026 JO - BMJ open DO - 10.1136/bmjopen-2026-118726 UR - https://doi.org/10.1136/bmjopen-2026-118726 ER -
APA
P, M., MJ, P., S, H. C., L, M., S, O., C, R., C, A., CM, P., J, Y., & JM, P. (2026). ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID.. BMJ open. https://doi.org/10.1136/bmjopen-2026-118726
Source records
- pubmed · retrieved 2026-09-26T15:42:34.802Z